pioglitazone has been researched along with Brain Inflammation in 15 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone treatment significantly improved LPS-induced neurobehavioral and physiological disturbances including the loss of body weight, hypothermia, righting reflex, wire-hanging maneuver, negative geotaxis, and hind-limb suspension in neonatal rats." | 5.62 | Pioglitazone Ameliorates Lipopolysaccharide-Induced Behavioral Impairment, Brain Inflammation, White Matter Injury and Mitochondrial Dysfunction in Neonatal Rats. ( Fan, LW; Kaizaki, A; Lee, JW; Ojeda, NB; Tien, LT; Tucci, MA; Wang, KC; Wei, HC; Yeh, JH, 2021) |
| "Pioglitazone treatment significantly improved LPS-induced neurobehavioral and physiological disturbances including the loss of body weight, hypothermia, righting reflex, wire-hanging maneuver, negative geotaxis, and hind-limb suspension in neonatal rats." | 1.62 | Pioglitazone Ameliorates Lipopolysaccharide-Induced Behavioral Impairment, Brain Inflammation, White Matter Injury and Mitochondrial Dysfunction in Neonatal Rats. ( Fan, LW; Kaizaki, A; Lee, JW; Ojeda, NB; Tien, LT; Tucci, MA; Wang, KC; Wei, HC; Yeh, JH, 2021) |
| "Treatment with Pioglitazone prevented the increase in the number of activated microglia and no difference was observed between sham and Pioglitazone-treated animals." | 1.37 | Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. ( Bing, G; Gao, J; Liu, M; Pauly, JR; Readnower, R; Sauerbeck, A; Sullivan, PG, 2011) |
| "Pioglitazone treatment reduced the infarct size and improved neurological functions." | 1.35 | Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia. ( Culman, J; Gohlke, P; Herdegen, T; Patzer, A; Stöck, I; Zhao, Y, 2008) |
| "Rosiglitazone treatment curtailed the post-ischemic expression of the pro-inflammatory genes interleukin-1beta, interleukin-6, macrophage inflammatory protein-1alpha, monocyte chemoattractant protein-1, cyclooxygenase-2, inducible nitric oxide synthase, early growth response-1, CCAAT/enhancer binding protein-beta and nuclear factor-kappa B, and increased the expression of the anti-oxidant enzymes catalase and copper/zinc-superoxide dismutase." | 1.34 | Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. ( Bowen, KK; Feinstein, DL; Kapadia, R; Liang, J; Satriotomo, I; Tureyen, K; Vemuganti, R, 2007) |
| "Pioglitazone or vehicle were i." | 1.33 | The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. ( Culman, J; Gohlke, P; Herdegen, T; Patzer, A; Zhao, Y, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Yeh, JH | 1 |
| Wang, KC | 1 |
| Kaizaki, A | 1 |
| Lee, JW | 1 |
| Wei, HC | 1 |
| Tucci, MA | 1 |
| Ojeda, NB | 1 |
| Fan, LW | 1 |
| Tien, LT | 1 |
| Omeragic, A | 1 |
| Hoque, MT | 1 |
| Choi, UY | 1 |
| Bendayan, R | 1 |
| Utreras, E | 1 |
| Hamada, R | 1 |
| Prochazkova, M | 1 |
| Terse, A | 1 |
| Takahashi, S | 1 |
| Ohshima, T | 1 |
| Kulkarni, AB | 1 |
| Ghavimi, H | 1 |
| Charkhpour, M | 1 |
| Ghasemi, S | 1 |
| Mesgari, M | 1 |
| Hamishehkar, H | 1 |
| Hassanzadeh, K | 2 |
| Arami, S | 1 |
| Patzer, A | 2 |
| Zhao, Y | 2 |
| Stöck, I | 1 |
| Gohlke, P | 2 |
| Herdegen, T | 2 |
| Culman, J | 2 |
| Sauerbeck, A | 1 |
| Gao, J | 1 |
| Readnower, R | 1 |
| Liu, M | 2 |
| Pauly, JR | 1 |
| Bing, G | 3 |
| Sullivan, PG | 1 |
| Semple, BD | 1 |
| Noble-Haeusslein, LJ | 1 |
| Carta, AR | 1 |
| Pisanu, A | 1 |
| Sundararajan, S | 1 |
| Gamboa, JL | 1 |
| Victor, NA | 1 |
| Wanderi, EW | 1 |
| Lust, WD | 1 |
| Landreth, GE | 1 |
| Maeda, T | 1 |
| Kiguchi, N | 1 |
| Fukazawa, Y | 1 |
| Yamamoto, A | 1 |
| Ozaki, M | 1 |
| Kishioka, S | 1 |
| Tureyen, K | 1 |
| Kapadia, R | 1 |
| Bowen, KK | 1 |
| Satriotomo, I | 1 |
| Liang, J | 1 |
| Feinstein, DL | 1 |
| Vemuganti, R | 1 |
| Klotz, L | 1 |
| Diehl, L | 1 |
| Dani, I | 1 |
| Neumann, H | 1 |
| von Oppen, N | 1 |
| Dolf, A | 1 |
| Endl, E | 1 |
| Klockgether, T | 1 |
| Engelhardt, B | 1 |
| Knolle, P | 1 |
| Xing, B | 2 |
| Xin, T | 1 |
| Hunter, RL | 1 |
1 review available for pioglitazone and Brain Inflammation
| Article | Year |
|---|---|
Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease?
Topics: Animals; Antiparkinson Agents; Encephalitis; Humans; Microglia; Parkinson Disease; Pioglitazone; PPA | 2013 |
14 other studies available for pioglitazone and Brain Inflammation
| Article | Year |
|---|---|
Pioglitazone Ameliorates Lipopolysaccharide-Induced Behavioral Impairment, Brain Inflammation, White Matter Injury and Mitochondrial Dysfunction in Neonatal Rats.
Topics: Animals; Animals, Newborn; Behavior, Animal; Cytokines; Electron Transport Complex I; Encephalitis; | 2021 |
Peroxisome proliferator-activated receptor-gamma: potential molecular therapeutic target for HIV-1-associated brain inflammation.
Topics: AIDS Dementia Complex; Animals; Encephalitis; HIV-1; Male; Pioglitazone; PPAR gamma; Rats; Rats, Wis | 2017 |
Suppression of neuroinflammation in forebrain-specific Cdk5 conditional knockout mice by PPARγ agonist improves neuronal loss and early lethality.
Topics: Animals; Apoptosis; Cyclin-Dependent Kinase 5; Cytokines; Disease Models, Animal; Encephalitis; Gene | 2014 |
Pioglitazone prevents morphine antinociceptive tolerance via ameliorating neuroinflammation in rat cerebral cortex.
Topics: Administration, Oral; Analgesics, Opioid; Anilides; Animals; Cerebral Cortex; Cytokines; Drug Tolera | 2015 |
Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia.
Topics: Animals; Anti-Inflammatory Agents; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Ence | 2008 |
Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury.
Topics: Analysis of Variance; Animals; Brain Injuries; CD11b Antigen; Cerebral Cortex; Cognition Disorders; | 2011 |
Broad-spectrum neuroprotection against traumatic brain injury by agonism of peroxisome proliferator-activated receptors.
Topics: Animals; Brain Injuries; Cerebral Cortex; Cognition Disorders; Disease Models, Animal; Encephalitis; | 2011 |
Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia.
Topics: Animals; Blood Glucose; Brain Chemistry; Cell Count; Cerebrovascular Circulation; Chromans; Dose-Res | 2005 |
The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain.
Topics: Animals; Brain; Brain Edema; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Encephalit | 2005 |
Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice.
Topics: Amphetamine-Related Disorders; Anilides; Animals; Behavior, Animal; Brain; Brain Chemistry; Cell Nuc | 2007 |
Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents.
Topics: Anilides; Animals; Cerebral Infarction; Chemotaxis, Leukocyte; Cytokines; Diabetes Mellitus, Type 2; | 2007 |
Brain endothelial PPARgamma controls inflammation-induced CD4+ T cell adhesion and transmigration in vitro.
Topics: Animals; Brain; CD4-Positive T-Lymphocytes; Cell Adhesion; Cell Line; Cerebral Arteries; Chemotaxis, | 2007 |
Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-kappaB and JNK activation and suppression of COX-2 activity.
Topics: Animals; Cells, Cultured; Cyclooxygenase 2; Dopamine; Dose-Response Relationship, Drug; Drug Interac | 2007 |
Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents; Brain; Cells, Cultured; Coculture Techniques; D | 2008 |